Saturn V Capital Management LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Saturn V Capital Management LP disclosed 24 US equity positions worth $255.4m in its Q4 2024 13F filing. The largest position was IRON at 12.6% of the reported book, followed by ASND and MLTX. Against the Q3 2024 filing, it opened 5 new positions, added to 9 and reduced 6 among the top 24 holdings.
What did Saturn V Capital Management LP own in Q4 2024? Top 24 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | IRON DISC MEDICINE INC | Healthcare | 12.6% | $32.3m | 509,406 | -0% | held |
| 2 | ASND ASCENDIS PHARMA A/S | Healthcare | 10.7% | $27.4m | 198,977 | -1% | reduced |
| 3 | MLTX MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | 7.3% | $18.7m | 346,111 | 16% | added |
| 4 | CGON CG ONCOLOGY INC | Healthcare | 6.7% | $17.0m | 593,262 | 14% | added |
| 5 | PCVX VAXCYTE INC | Healthcare | 6.5% | $16.7m | 204,285 | -0% | held |
| 6 | CYTK CYTOKINETICS INC | Healthcare | 6.4% | $16.4m | 348,364 | 5% | added |
| 7 | CRGX CARGO THERAPEUTICS INC | 5.7% | $14.5m | 1,007,677 | 1% | added | |
| 8 | CELC CELCUITY INC | Healthcare | 5.5% | $13.9m | 1,063,783 | 12% | added |
| 9 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 5.1% | $13.1m | 988,528 | 97% | added |
| 10 | XENE XENON PHARMACEUTICALS INC | Healthcare | 5.0% | $12.6m | 322,470 | – | new |
| 11 | ARGX ARGENX SE | Healthcare | 4.8% | $12.1m | 19,754 | -11% | reduced |
| 12 | COGT COGENT BIOSCIENCES INC | Healthcare | 4.6% | $11.7m | 1,498,425 | -13% | reduced |
| 13 | MERUS N V | 3.9% | $9.9m | 234,637 | 79% | added | |
| 14 | CTNM CONTINEUM THERAPEUTICS INC | 3.3% | $8.4m | 573,022 | 641% | added | |
| 15 | ABVX ABIVAX SA | 1.9% | $4.8m | 653,071 | 1% | added | |
| 16 | 4XC1 KALVISTA PHARMACEUTICALS INC | 1.8% | $4.7m | 556,489 | 0% | held | |
| 17 | INOZYME PHARMA INC | 1.5% | $3.8m | 1,374,582 | 0% | held | |
| 18 | IRWD IRONWOOD PHARMACEUTICALS INC | Healthcare | 1.4% | $3.6m | 814,533 | -27% | reduced |
| 19 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.3% | $3.4m | 889,073 | – | new |
| 20 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.2% | $3.0m | 59,125 | -46% | reduced | |
| 21 | SLN SILENCE THERAPEUTICS PLC | 1.1% | $2.7m | 395,024 | -18% | reduced | |
| 22 | NEWAMSTERDAM PHARMA COMPANY | 1.0% | $2.6m | 100,000 | – | new | |
| 23 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 0.6% | $1.6m | 191,456 | – | new |
| 24 | MBX MBX BIOSCIENCES INC | Healthcare | 0.1% | $331.7k | 18,000 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.